STOCK TITAN

Reid Hoffman/Form 4 reports 98,387 VOR shares sold, 1.50M held

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Vor Biopharma Inc. reporting persons Reprogrammed Interchange LLC and Reid Hoffman disclosed multiple open-market sales of common stock on 10/06/2025 and 10/07/2025. The filings show four sale lines: 17,760 shares at a weighted average price of $36.0018, 34,847 shares at $37.1213, 18,156 shares at $37.7743, and 27,624 shares at $33.8369. After these transactions, the reporting entity held 1,498,921 shares directly.

The document clarifies that the reported prices are weighted averages from multiple trades and that Mr. Hoffman may be deemed an indirect beneficial owner of the shares held by Reprogrammed but disclaims ownership except for his pecuniary interest. Signatures for Reid Hoffman and Frank Huang (Manager of Reprogrammed Interchange LLC) appear with dates of 10/08/2025.

Positive

  • None.

Negative

  • None.

Insights

Insider sales were disclosed across multiple dates with remaining large direct holdings.

The sales reduce direct holdings from prior totals to 1,498,921 shares held by the reporting entity, indicating continued ownership while realizing liquidity. The filing uses standard disclosure language noting weighted average prices and multiple trade executions.

Key dependencies include whether additional scheduled sales exist and the reporting persons' continued roles; monitor any future Form 4 filings within several weeks for further reductions or changes in ownership.

Aggregate disclosed sales totaled 98,387 shares across two trading dates.

Those sales occurred at weighted average prices between $33.8369 and $37.7743, which may modestly affect float depending on daily volume. The filing does not state any 10b5-1 plan; instead it reports standard open-market transactions executed in multiple trades.

Watch trading volumes and subsequent Form 4 entries over the next 30 days to gauge whether these are isolated liquidity events or part of a larger, ongoing disposition.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Reprogrammed Interchange LLC

(Last) (First) (Middle)
101 MISSION STREET, SUITE 1000

(Street)
SAN FRANCISCO CA 94105

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Vor Biopharma Inc. [ VOR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/06/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/06/2025 S 17,760 D $36.0018(1) 1,579,548(2) D
Common Stock 10/06/2025 S 34,847 D $37.1213(3) 1,544,701(2) D
Common Stock 10/06/2025 S 18,156 D $37.7743(4) 1,526,545(2) D
Common Stock 10/07/2025 S 27,624 D $33.8369(5) 1,498,921(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
Reprogrammed Interchange LLC

(Last) (First) (Middle)
101 MISSION STREET, SUITE 1000

(Street)
SAN FRANCISCO CA 94105

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Hoffman Reid

(Last) (First) (Middle)
101 MISSION STREET, SUITE 1000

(Street)
SAN FRANCISCO CA 94105

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. This transaction was executed in multiple trades at prices ranging from $35.59 to $36.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
2. The securities are held by Reprogrammed Interchange LLC ("Reprogrammed"). Reid Hoffman may be deemed a beneficial owner of securities held by Reprogrammed by virtue of his shared control over and indirect pecuniary interest in Reprogrammed. Mr. Hoffman disclaims beneficial ownership of the securities held by Reprogrammed, except to the extent of his pecuniary interest therein.
3. This transaction was executed in multiple trades at prices ranging from $36.59 to $37.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
4. This transaction was executed in multiple trades at prices ranging from $37.59 to $38.18 The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
5. This transaction was executed in multiple trades at prices ranging from $33.70 to $34.27. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
/s/ Reid Hoffman 10/08/2025
/s/ Frank Huang, Manager of Reprogrammed Interchange LLC 10/08/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Vor Biopharma Inc.

NASDAQ:VOR

VOR Rankings

VOR Latest News

VOR Latest SEC Filings

VOR Stock Data

300.39M
37.51M
39.09%
43.63%
15.62%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
BOSTON